This review synthesizes current evidence on how endometrial polyps, leiomyomas, adenomyosis, and endometriosis influence endometrial receptivity, emphasizing phenotype-specific effects, molecular mechanisms, and implications for embryo transfer outcomes.
In Japan, the microwave endometrial ablation system (MEA, Microsulis PLC, Waterlooville, UK) is the most widely used device for endometrial ablation and is considered a minimally invasive, uterus-preserving treatment for …
Adenomyosis is a prevalent disorder of the archimetra, historically conflated with endometriosis but possessing a unique pathobiological trajectory. This review synthesises current molecular evidence to propose a unified mechanistic framework …
Adenomyosis is a heterogeneous, nonmalignant uterine disorder characterized by ectopic endometrium within the myometrium, leading to abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and subfertility. Once considered a disease of …
Female reproductive disorders represent a major global health challenge. Despite their clinical heterogeneity, these conditions share core pathological mechanisms including oxidative stress, chronic inflammation, hormonal imbalance, metabolic dysfunction, extracellular matrix …
Cystic adenomyoma is a rare focal cystic variant of adenomyosis, and giant lesions are particularly uncommon. Malignant transformation has been reported in endometriosis-related disease, but the molecular features of cystic …
Uterine leiomyomas or fibroids, are non-cancerous smooth muscle proliferations of the uterus, occurring mostly in women of reproductive age. Their pathogenesis involves complex growth factor interactions that regulate cellular proliferation, …
Abnormal uterine bleeding (AUB), particularly when associated with uterine leiomyomas, is a frequent cause of iron deficiency anemia among women of reproductive age. While commonly manageable, in rare instances, AUB …
Both endometriosis and adenomyosis can impact quality of life. Endometriosis is a chronic, benign, condition characterized by the growth of endometrium outside the uterus, which affects ~10% of women from …
Relugolix, an oral GnRH receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol …